Wall Street analysts forecast that Strongbridge Biopharma PLC (NASDAQ:SBBP) will post earnings of ($0.42) per share for the current quarter, Zacks reports. Three analysts have provided estimates for Strongbridge Biopharma PLC’s earnings. The highest EPS estimate is ($0.38) and the lowest is ($0.48). Strongbridge Biopharma PLC reported earnings of ($0.36) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 16.7%. The company is scheduled to issue its next earnings results before the market opens on Tuesday, November 14th.
On average, analysts expect that Strongbridge Biopharma PLC will report full-year earnings of ($2.66) per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of ($1.27) per share, with EPS estimates ranging from ($1.65) to ($0.93). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Strongbridge Biopharma PLC.
Several research firms have recently weighed in on SBBP. Oppenheimer Holdings, Inc. began coverage on Strongbridge Biopharma PLC in a research report on Thursday, August 10th. They set an “outperform” rating and a $12.00 target price for the company. Zacks Investment Research upgraded Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating and set a $7.25 target price for the company in a research report on Wednesday, October 11th. Finally, ValuEngine downgraded Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $11.81.
WARNING: This story was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/11/12/strongbridge-biopharma-plc-sbbp-expected-to-post-earnings-of-0-42-per-share.html.
Several institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System purchased a new position in shares of Strongbridge Biopharma PLC during the second quarter valued at $277,000. State Street Corp purchased a new position in shares of Strongbridge Biopharma PLC during the second quarter valued at $443,000. Nexthera Capital LP purchased a new position in shares of Strongbridge Biopharma PLC during the second quarter valued at $477,000. Vanguard Group Inc. purchased a new position in shares of Strongbridge Biopharma PLC during the second quarter valued at $474,000. Finally, Northern Trust Corp purchased a new position in shares of Strongbridge Biopharma PLC during the second quarter valued at $1,462,000. Hedge funds and other institutional investors own 56.53% of the company’s stock.
Strongbridge Biopharma PLC (SBBP) traded up $0.10 during trading hours on Friday, hitting $6.00. The stock had a trading volume of 72,500 shares, compared to its average volume of 138,715. Strongbridge Biopharma PLC has a fifty-two week low of $2.00 and a fifty-two week high of $8.85. The company has a quick ratio of 4.46, a current ratio of 4.63 and a debt-to-equity ratio of 1.89.
About Strongbridge Biopharma PLC
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.